Share price · BLRX
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when BLRX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 16 Nov 2026-11.5%
- 12 Nov 2026-9.4%
Nothing announced by BLRX that day or the session before.
- 9 Nov 2026-7.6%
Nothing announced by BLRX that day or the session before.
- 20 Oct 2026+11.8%
Nothing announced by BLRX that day or the session before.
- 28 Sep 2026-6.5%
Nothing announced by BLRX that day or the session before.
- 23 Sep 2026+5.3%
Nothing announced by BLRX that day or the session before.
- 31 Aug 2026+7.7%
- 24 Aug 2026+6.8%
Nothing announced by BLRX that day or the session before.
- 18 Aug 2026+8.0%
- 30 Apr 2026-10.4%
Nothing announced by BLRX that day or the session before.
Share of unusual movement by asset
For each asset, the share of BLRX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
Motixafortideevents and moves
| 3 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 0% |
| Other company news (earnings, financing, releases naming no asset) | — | 0% |
| Sessions with no dated event | — | 100% |
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | CXCR4Peptide | Multiple MyelomaPancreatic Cancer |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
November 2026 (1)
What to watch
Financial reports
Quarterly & interim (4)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-Q2 | $0.3M | $2.3M | $7.2M | $3.9M | report ↗ |
BioLineRx Ltd. reported revenue of $0.3M, down 94.4% YoY, R&D spend of $2.33M, up 4.5% YoY, cash and equivalents of $7.19M, and a net loss of $3.94M for Q2 2025.
Figures only: this period's report disclosed no narrative text
View 3 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-Q2 | $5.4M | $2.2M | $9.6M | — | report ↗ |
| 2023-Q2 | $0 | $3.0M | $10M | $19M | report ↗ |
| 2022-Q2 | — | $5.4M | $14M | $7.4M | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $1.2M | $8.1M | $3.3M | $0.5M-$8.1M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
No Form 4 transactions on file in the stored window.
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 12 reporting institutions held 0.0M shares ($45K, 0.4% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | XTX Topco Ltd | 10,941 | $25K |
| 2 | RHUMBLINE ADVISERS | 2,353 | $5K |
| 3 | BNP PARIBAS FINANCIAL MARKETS | 1,800 | $4K |
| 4 | WELLS FARGO & COMPANY/MN | 1,750 | $4K |
| 5 | CITIGROUP INC | 1,728 | $4K |
| 6 | UBS Group AG | 529 | $1K |
| 7 | Nemes Rush Group LLC | 250 | $575 |
| 8 | MORGAN STANLEY | 100 | $230 |
| 9 | OSAIC HOLDINGS, INC. | 26 | $59 |
| 10 | Rockefeller Capital Management L.P. | 12 | $28 |
| 11 | DANSKE BANK A/S | 2 | $5 |
| 12 | Banque Cantonale Vaudoise | 1 | $0 |